• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Turn Therapeutics Inc. - Common Stock (NQ:TTRX)

4.880 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Jan 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Turn Therapeutics Inc. - Common Stock

News headline image
Turn Therapeutics Announces Corporate and Pipeline Updates and 2026 Outlook Ahead of the 44th Annual J.P. Morgan Healthcare Conference
January 12, 2026
From Turn Therapeutics, Inc.
Via Business Wire
News headline image
Turn Therapeutics Appoints Martin Dewhurst to its Board of Directors
January 07, 2026
Mr. Dewhurst Brings Over 30 Years of Life Sciences and M&A Experience to the Board, Aligning with the Company’s Strategic Long-Term Goals for Growth and Expansion 
From Turn Therapeutics
Via GlobeNewswire
News headline image
Turn Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Updates
November 13, 2025
From Turn Therapeutics
Via GlobeNewswire
News headline image
Turn Therapeutics CEO, Bradley Burnam, Speaks with Former Director of the Centers for Disease Control and Prevention Dr. Robert Redfield, M.D.
November 11, 2025
Conversation Centered Around Healthcare Communications and Pandemic Preparedness 
From Turn Therapeutics
Via GlobeNewswire
News headline image
Turn Therapeutics’ GX-03 Technology Named as One of “Five Novel Mechanisms Reshaping Atopic Dermatitis Treatment” by Patient Care Online Magazine
November 11, 2025
Turn’s Topical IL36/IL31 Inhibitor Named Alongside Other Phase 2 & 3 Candidates from Amgen, Sanofi, Leo Pharma, Apogee Therapeutics, and Nektar Therapeutics 
From Turn Therapeutics
Via GlobeNewswire
News headline image
Turn Therapeutics Appoints Veteran Capital Markets Executive Andrew Scott as Vice President of Corporate Communications
November 04, 2025
From Turn Therapeutics
Via GlobeNewswire
News headline image
Turn Therapeutics Enters Global Supply, Development, and License Agreement with Leading Medical-Surgical Product Manufacturer and Distributor Medline
October 30, 2025
Agreement combines Turn’s PermaFusion® delivery platform with Medline’s global scale and distribution capabilities to advance professional and retail product opportunities 
From Turn Therapeutics
Via GlobeNewswire
News headline image
Turn Therapeutics Provides Shareholder Update Highlighting Continued Execution Across Clinical and Strategic Milestones
October 22, 2025
Company to host shareholder webinar today, October 22, 2025, at 2:00 PM ET to review execution milestones, pipeline progress, and capital strategy 
From Turn Therapeutics
Via GlobeNewswire
News headline image
Turn Therapeutics Launches Webinar Series for Ongoing Shareholder Engagement, First Session October 22, 2025
October 20, 2025
From Turn Therapeutics
Via GlobeNewswire
News headline image
Turn Therapeutics Appoints Dr. Kent Kester to Board of Directors
October 15, 2025
Seasoned clinician and R&D leader brings extensive experience in translational medicine, drug development, and infectious disease research 
From Turn Therapeutics
Via GlobeNewswire
News headline image
Turn Therapeutics Appoints Arthur Golden to Board of Directors
October 14, 2025
Veteran corporate advisor to strengthen governance, oversight, and strategic execution as the Company advances late-stage programs 
From Turn Therapeutics
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap